Faes Farma (Spain)

Recent papers from Faes Farma (Spain)

1. Weekly Calcifediol 100 µg in Women with Vitamin D Deficiency: A Post Hoc Analysis of a Randomised Placebo-Controlled Phase II/III TrialNutrients · 2026
2. Associations between animal welfare, gut microbiota composition, and intestinal integrity during weaning in pigletsThe Veterinary Journal · 2026
3. Vitamin D in the prevention of left ventricular remodelling after an acute myocardial infarction: a randomized clinical trialScientific Reports · 2026
4. Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution in Children and Adolescents: An 8-Week Phase 3 StudyJournal of Investigational Allergology and Clinical Immunology · 2026
5. Efficacy and Safety of Amino Acid–Enriched Hyaluronic Acid in Facial Rejuvenation: A Systematic Review and Meta‐AnalysisJournal of Cosmetic Dermatology · 2026
6. P1109Impact of concomitant mesalazine administration on the efficacy and safety of advanced therapies in ulcerative colitis: a meta-analysis over the induction and maintenance phasesJournal of Crohn s and Colitis · 2026
7. Orolabial and Genital Herpes Clinical Trials: A Meta-analysis of EndpointsOpen Forum Infectious Diseases · 2025
8. Safety, Pharmacokinetics, and Bioequivalence Characterization of Two Different Strengths of Mesalazine Gastro-Resistant TabletsPharmaceuticals · 2025
9. Emerging Age-Specific Therapeutic Approaches for Dry Eye DiseaseJournal of Clinical Medicine · 2025
10. The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro studyScientific Reports · 2025
11. Bioequivalence Study of Two Oral Methocarbamol Formulations in Healthy Subjects Under Fasting Conditions: A Randomized, Open-Label, Crossover Clinical TrialSHILAP Revista de lepidopterología · 2025
12. A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D DeficiencyNutrients · 2025
13. Ophthalmic Formulations for the Treatment of Allergic Conjunctivitis and Their Effect on the Ocular Surface: A Review of Safety and Tolerability Assessments in Clinical TrialsJournal of Clinical Medicine · 2024
14. Bioequivalence and Safety of Bilastine 20 mg Orodispersible Tablets and Conventional Tablets: A Randomized, Single-Dose, Two-Period Crossover Study in Healthy Volunteers Under Fasting ConditionsDrugs in R&D · 2024
15. Structural diversification of vitamin D using microbial biotransformationsApplied Microbiology and Biotechnology · 2024
16. Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical TrialJournal of Investigational Allergology and Clinical Immunology · 2024
17. The new preservative-free ophthalmic formulation of bilastine 0.6% preserves the ocular surface epithelial integrity in a comparative in vitro studyScientific Reports · 2024
18. Efficacy and Safety of Calcifediol in Young Adults with Vitamin D Deficiency: A Phase I, Multicentre, Clinical Trial—POSCAL StudyNutrients · 2024
19. Fundamental Aspects and Relevance of Components in Antihistamine Eye DropsJournal of Investigational Allergology and Clinical Immunology · 2023
20. Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic ConjunctivitisJournal of Investigational Allergology and Clinical Immunology · 2023